- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Adherence to interferon β-1a therapy using an electronic...
Open Collections
UBC Faculty Research and Publications
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study Devonshire, Virginia A; Feinstein, Anthony; Moriarty, Patrick
Abstract
Background: In a multicentre, single-arm, observational, phase IV study, we evaluated 24-week treatment adherence of relapsing multiple sclerosis (RMS) patients using an electronic auto-injection device (RebiSmart®) for subcutaneous injection of interferon (IFN) β-1a. Methods: A total of 162 adult participants with RMS were enrolled into the study to use RebiSmart® to self-administer IFN β-1a 44 μg three times weekly for a maximum of 96 weeks. The number of administered injections was recorded in the electronic device log. Adherence to treatment was defined as the administration of ≥80 % of expected injections. Cognitive impairment and injection anxiety were assessed via questionnaires. Results: Overall, 91.8 and 82.9 % of participants were adherent to treatment at weeks 12 and 24, respectively. By weeks 12 and 24, 8.2 and 13.9 % of participants had discontinued treatment. There were no statistically significant differences in adherence rates at weeks 12 and 24 according to cognitive impairment status or injection anxiety. By week 24, 69.9 % of participants were less fearful of injection than when they started the study. According to participant evaluations, the absence of a visible needle, comfort settings, and the calendar for tracking the injection schedule were all important features of the RebiSmart® injection system. At week 24, 99.3 % of participants reported that they would like to continue using RebiSmart® as their injector. Conclusions: RebiSmart® use is associated with high treatment adherence, as objectively assessed using electronic injection logs. Future research should examine if RebiSmart® use improves long-term treatment outcomes in RMS. This study was registered with ClinicalTrials.gov as NCT01128075, on May 20, 2010.
Item Metadata
Title |
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study
|
Creator | |
Publisher |
BioMed Central
|
Date Issued |
2016-03-08
|
Description |
Background:
In a multicentre, single-arm, observational, phase IV study, we evaluated 24-week treatment adherence of relapsing multiple sclerosis (RMS) patients using an electronic auto-injection device (RebiSmart®) for subcutaneous injection of interferon (IFN) β-1a.
Methods:
A total of 162 adult participants with RMS were enrolled into the study to use RebiSmart® to self-administer IFN β-1a 44 μg three times weekly for a maximum of 96 weeks. The number of administered injections was recorded in the electronic device log. Adherence to treatment was defined as the administration of ≥80 % of expected injections. Cognitive impairment and injection anxiety were assessed via questionnaires.
Results:
Overall, 91.8 and 82.9 % of participants were adherent to treatment at weeks 12 and 24, respectively. By weeks 12 and 24, 8.2 and 13.9 % of participants had discontinued treatment. There were no statistically significant differences in adherence rates at weeks 12 and 24 according to cognitive impairment status or injection anxiety. By week 24, 69.9 % of participants were less fearful of injection than when they started the study. According to participant evaluations, the absence of a visible needle, comfort settings, and the calendar for tracking the injection schedule were all important features of the RebiSmart® injection system. At week 24, 99.3 % of participants reported that they would like to continue using RebiSmart® as their injector.
Conclusions:
RebiSmart® use is associated with high treatment adherence, as objectively assessed using electronic injection logs. Future research should examine if RebiSmart® use improves long-term treatment outcomes in RMS.
This study was registered with ClinicalTrials.gov as NCT01128075, on May 20, 2010.
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2018-05-16
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution 4.0 International (CC BY 4.0)
|
DOI |
10.14288/1.0366891
|
URI | |
Affiliation | |
Citation |
BMC Research Notes. 2016 Mar 08;9(1):148
|
Publisher DOI |
10.1186/s13104-016-1948-z
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty
|
Copyright Holder |
Devonshire et al.
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution 4.0 International (CC BY 4.0)